In Japan, Professor Masanori Kataoka finds that the ACQUITY QDa Mass Detector is suitable for the synthesis and analysis of oligonucleotides – and sees ways to expand its use.
There are two primary multi-attribute monitoring (MAM) assay choices for biologic development and QC: subunit protein mass analysis and peptide mapping by LC-MS. Here we explore how peptide mapping LC-MS MAM workflows are being used.
You won’t like what we found when we tested skin lightening cosmetics that we purchased online.
Choosing the right technology is crucial – so it’s great when innovation makes the decision clear-cut. With Gerard Rosse, Associate Director, Structure Guided Chemistry at Dart NeuroScience.
What are the challenges when translating complexity into simplicity – and how do we measure success in such an endeavor? Daniel Kenny, Director of MS Development at Waters, shares the motivation, inspiration and celebration behind… Read more >
With access to multiple mass spectrometry systems of varying degrees of sophistication, Davy Guillarme (University of Geneva, Switzerland) wasn’t actively looking for new mass detection solutions. Nevertheless, the Waters ACQUITY QDa mass detector caught his eye.
At Reach Separations, they’re putting robust detection on the front lines of method development and mass confirmation.
Lion, one of the largest food and beverage companies in Australia and New Zealand, wanted to monitor fermentation profiles to completion as the company introduced voluntary nutritional panels across its beer portfolio. See what they gained by changing from electrochemical to mass detection.
The quality issues of biopharmaceutical therapeutics are definitely different from chemical drugs because of the increased complexity of manufacturing processes and complexity of the biologic molecules themselves. There is an increasing need for detailed product… Read more >
As regulators focus in on the critical quality attributes of biotherapeutics, what can biopharmaceutical labs in late development or QC do to increase confidence in their bioseparations – other than to run more assays?